RxDoctor Payments Data

Ardis Moe, MD

Infectious Disease · Los Angeles, CANPI 1851408876

Payments from drug & device makers

$11,225in general payments, 2019–2025

Across 523 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$6K
  • Gilead$3K
  • Merck$948
  • AbbVie$831
  • Johnson & Johnson$432
  • Janssen Products, LP$199
  • plus $457 from 6 others

What the payments were for

  • Food & beverage$10,99698%
  • Education$2292%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$11,225 in reported general payments places this provider in the 80th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$114,174
Medicare patients
183
Services billed
1,501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala475$1,853,307
TivicayDolutegravir Sodium323$881,127
GenvoyaElviteg/Cob/Emtri/Tenof Alafen184$729,665
DescovyEmtricitabine/Tenofov Alafenam245$607,520
TriumeqAbacavir/Dolutegravir/Lamivudi132$539,976
CabenuvaCabotegravir/Rilpivirine81$512,625
PifeltroDoravirine214$407,685
DovatoDolutegravir Sodium/Lamivudine126$392,263
IsentressRaltegravir Potassium169$370,462
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf62$344,716
OdefseyEmtricitab/Rilpiviri/Tenof Ala59$243,463
SerostimSomatropin11$224,481
PrezcobixDarunavir/Cobicistat84$211,320
JulucaDolutegravir/Rilpivirine56$186,280
Maraviroc106$125,060

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$2,525$3,190,492904 claims
Viiv Healthcare CompanyTivicay, Triumeq, Cabenuva, Dovato, Juluca$5,833$2,512,271718 claims
MerckPifeltro, Isentress$948$778,147383 claims
Janssen Products, LPSymtuza$199$344,71662 claims
Johnson & JohnsonPrezcobix, Xarelto$432$245,752139 claims
EMD Serono, Inc.Serostim$199$224,48111 claims
Boehringer IngelheimAptivus, Jardiance$19$42,75738 claims
AbbVieViberzi$831$18,30712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 856 infectious disease providers in California.

Other infectious disease in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →